TrialHepatology (Baltimore, Md.)2011

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Alexander J Thompson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.